Abstract
Parkinson’s disease (PD) is the second-most common neurodegenerative disease after Alzheimer’s disease. The most important pathological feature of PD is the irreversible damage of dopamine neurons, which is related to autophagy and neuroinflammation in the substantia nigra. Previous studies found that the activation of NAcht Leucine-rich repeat Protein 3 (NLRP3) inflammasome/pyroptosis and cell division protein kinase 5 (CDK5)-mediated autophagy played an important role in PD. Bioinformatics analyses further predicted that microRNA (miR)-188-3p potentially targets NLRP3 and CDK5. Adipose-derived stem cell (ADSC)-derived exosomes were found to be excellent vectors for genetic therapy. We assessed the levels of injury, autophagy, and inflammasomes in 1-methyl-4-phenyl-1,2,4,5-tetrahydropyridine (MPTP)-induced PD mice models and neurotoxin 1-methyl-4-phenylpyridinium (MPP+)-induced cell models after treating them with miR-188-3p-enriched exosomes. miR-188-3p-enriched exosome treatment suppressed autophagy and pyroptosis, whereas increased proliferation via targeting CDK5 and NLRP3 in mice and MN9D cells. It was revealed that mir-188-3p could be a new therapeutic target for curing PD patients.
Highlights
Parkinson’s disease (PD) is a common chronic progressive neurodegenerative disorder that affects 2%–3% of the population R65 years of age and is more popular among those >80 years of age.[1]
Results showed that Adipose-derived stem cell (ADSC) were positive for the mesenchymal stem cell (MSC) markers CD29, CD44, CD90, and CD105 (Figure 2C)
The exosomes of 50À120 nm in diameter secreted by ADSCs were photographed using transmission electron microscopy (TEM) (Figure 2D)
Summary
Parkinson’s disease (PD) is a common chronic progressive neurodegenerative disorder that affects 2%–3% of the population R65 years of age and is more popular among those >80 years of age.[1]. It is important and promising to study miRNA-overexpressed, ADSC-derived exosome treatment in PD
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
